"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.
Descriptor ID |
D018394
|
MeSH Number(s) |
D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
|
Concept/Terms |
CA-125 Antigen- CA-125 Antigen
- Antigen, CA-125
- Antigen CA-125
- Antigen CA 125
- Mucin-16
- Mucin 16
- CA 125 Antigen
- Antigen, CA 125
|
Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Mucoproteins [D12.776.395.560]
- Mucins [D12.776.395.560.631]
- CA-125 Antigen [D12.776.395.560.631.050]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
- CA-125 Antigen [D23.050.285.050.225]
- Epitopes [D23.050.550]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
- CA-125 Antigen [D23.050.550.325.225]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
- CA-125 Antigen [D23.101.140.075.225]
Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".
This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 1 | 2 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2011 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
2020 | 0 | 2 | 2 |
2021 | 0 | 2 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Necessity of posttreatment surveillance for low-grade appendiceal mucinous neoplasms. J Surg Oncol. 2021 Dec; 124(7):1115-1120.
-
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunol Invest. 2021 Jul; 50(5):562-579.
-
Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
-
Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol. 2017 12; 217(6):652-660.
-
Applicability of the modified ACOG/SGO referral criteria for adnexal mass within a limited-resource setting. Int J Gynaecol Obstet. 2017 Jan; 136(1):53-57.
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
-
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011; 6(12):e29180.
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.